Hyperhidrosis treatment with bornaprine in the acute phase of spinal cord-injured patients

9Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Study design: Original article. Objective: To test the use of bornaprine in the hyperhidrosis treatment in the acute phase of spinal cord-injured patients. Setting: Patients with acute spinal cord lesions in the Spinal Unit of Pietra Ligure, Savona, Italy. Method: In 4 years, 12 patients have been treated, for a maximum period of 75 days, with dosages ranging from 2 to 4 mg day-1. Results: All of them reported long-lasting subjective benefits, without side effects, even after the interruption of the therapy. Conclusion: The bornaprine treatment, at 2 or 4 mg day-1 dosage, has been effective and safe to contrast hyperhidrosis, in the acute phase of spinal cord-injured patients. This positive experience would require additional trials and a larger number of cases to gain a more solid support. © 2008 International Spinal Cord Society All rights reserved.

Cite

CITATION STYLE

APA

Sergi, R., Massone, A., Moretto, S., Oggerino, C., Bertolotto, F., Losio, L., & Ottonello, M. (2008). Hyperhidrosis treatment with bornaprine in the acute phase of spinal cord-injured patients. Spinal Cord, 46(8), 571–573. https://doi.org/10.1038/sc.2008.12

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free